Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension
Autore:
Oparil, S; Aurup, P; Snavely, D; Goldberg, A;
Indirizzi:
Merck & Co Inc, Worldwide Human Hlth, Clin Dev Program Studies, Hypertens HF IHD, Whitehouse Stn, NJ 08889 USA Merck & Co Inc Whitehouse Stn NJ USA 08889 , Whitehouse Stn, NJ 08889 USA Univ Alabama, Birmingham, AL USA Univ Alabama Birmingham AL USAUniv Alabama, Birmingham, AL USA Merck Res Labs, Dept Stat & Clin Dev, Blue Bell, PA USA Merck Res Labs Blue Bell PA USA Dept Stat & Clin Dev, Blue Bell, PA USA
Titolo Testata:
AMERICAN JOURNAL OF CARDIOLOGY
fascicolo: 6, volume: 87, anno: 2001,
pagine: 721 - 726
SICI:
0002-9149(20010315)87:6<721:EASOLI>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
II RECEPTOR ANTAGONIST; LOSARTAN PLUS HYDROCHLOROTHIAZIDE; LOW-DOSE HYDROCHLOROTHIAZIDE; ANGIOTENSIN-II; THERAPY; COMBINATION; POTASSIUM; TOLERABILITY; DUP-753;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
18
Recensione:
Indirizzi per estratti:
Indirizzo: Aurup, P Merck & Co Inc, Worldwide Human Hlth, Clin Dev Program Studies, Hypertens HF IHD, 1 Merck Dr,POB 100,WS3C-60, Whitehouse Stn, NJ 08889 USA Merck & Co Inc 1 Merck Dr,POB 100,WS3C-60 Whitehouse Stn NJ USA 08889
Citazione:
S. Oparil et al., "Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension", AM J CARD, 87(6), 2001, pp. 721-726

Abstract

This 12-week, open-label, multicenter study assessed the efficacy and safety of losartan/hydrochlorothiazide (HCTZ), alone or in combination with other antihypertensive agents, in the treatment of patients with severe systemic hypertension. Treatment began with once-daily losartan/HCTZ 50/12.5 mg. The dose was increased to 100/25 mg, if required, to achieve brood pressure(BP) control (sitting diastolic BP <95 mm Hg); felodipine (extended release) and/or atenolol could be added if target sitting diastolic BP was not achieved with losartan/HCTZ alone. Mean sitting systolic BP of the 131 patients enrolled was 165.3 mm Hg at baseline and 139.8 mm Hg at final visit (reduction -25.4 mm Hg; p <less than or equal to>0.01). Mean sitting diastolic BP was 111.9 mm Hg at baseline and 93.6 mm Hg at final visit (reduction -18.4 mm Hg; p less than or equal to0.01). After 2 weeks of treatment, 63.8% of patients (83 of 130) were taking losartan/HCTZ 50/12.5 mg alone. By the final visit, one third of patients (35.1%; 46/131) were still only taking losartan/HCTZ. Most patients (48.1%; 63 of 131) were taking losartan/HCTZ 100/25 mg plus felodipine (extended release) at the final visit. Losartan/HCTZwas well tolerated. Drug-related adverse experiences occurred in 30 patients (22.9%). Only 2 patients (1.5%) had a serious adverse experience; 6 patients (4.6%) discontinued the drug because of an adverse experience, In conclusion, losartan/ HCTZ, alone or as part of a regimen with other standard antihypertensive agents, is effective and well tolerated in the treatment ofpatients with severe hypertension. (C) 2001 by Excerpta Medica, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 08:21:39